INFINIUM PATHOLOGY CONSULTANTS - Key Persons
Job Titles:
- Senior Consultant, Medical Writer
Job Titles:
- Senior Consultant, Preclinical Translation
Dr. Robertson brings more than 20 years of experience in drug development to her role as a consultant medical writer for Infinium Pathology. She has worked for pharmaceutical, biotechnology, and medical device companies in addition to contract research organizations. Her broad-based background includes design, implementation, and management of both preclinical and clinical studies. As a result, she has a detailed understanding of both GLP and GCP guidelines. She has extensive writing experience including protocols and study reports, documents for regulatory submission (e.g., INDs, annual reports/DSURs, briefing documents), and documents for publication (e.g., abstracts, journal articles). Before moving to industry, Dr. Robertson obtained her Ph.D. in Microbiology/Virology from Va. Tech, received an NCI postdoctoral fellowship grant for postdoctoral study at LSU Medical Center, and was a Senior Staff Fellow at the National Institute of Environmental Health Sciences.
Elias served as a Scientist at Tengion, Inc. for six year and has over 18 years of Broad-based background in preclinical (GLP and Non-GLP) experimental studies including the histological and biocompatibility evaluation of human and animal tissues for safety assessment of medical devices, biomaterials and regenerative medicine products; direct experience in design and implementation of preclinical studies from start-up through closeout. Elias earned his Master of Health Science (Medical Laboratory Science) from Quinnipiac University in 1999 and his Bachelor of Science in Microbiology in 1996 from Southern Connecticut State University..
Job Titles:
- Scientific Advisor, Preclinical Translation
Dr. Basu served as a Director of Process Research and Translation at Tengion, Inc. for six years. Responsibilities included potency assay development and determination of biodistribution and mechanism of action for Tengion's clinical candidates Neo-Urinary Conduit (NUC) and Neo-Kidney Augment (NKA). Joydeep also led development of Tengion's Neo-Esophagus and Neo-Intestine preclinical programs. Prior to joining Tengion in 2008, Joydeep spearheaded preclinical translation of Multi-stem and led development of the human artificial chromosome gene therapy platform at Athersys, Inc. Joydeep received his PhD from Cornell University in 1999 and his BA from the University of Cambridge in 1993.